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Background: Dedifferentiated chondrosarcomas consist of two distinguishable components: low-grade
chondrosarcoma components and high-grade dedifferentiated components.
Materials and methods: Nine cases (4 males, 5 females) of dedifferentiated chondrosarcoma were treated in our
institute. The average age was 58.6 (range, 37–86) years. The tumor location was the long bone in 7 cases (femur,
n=5; humerus, n=1; tibia, n=1) and the pelvic bone in 2 cases. The average time from appearance of symptoms to
treatment was 9.4 (range, 1–40) months.
Results and discussion: On plain radiographs, matrix mineralization was seen in all 9 cases (100%). Bone
destruction was observed in 5 of 9 cases (56%), while pathological fracture was seen in one femur case (11%). Lung
metastasis was observed in all cases (initially in 5 cases; during the treatment course in 4 cases). Surgery was
performed in 8 cases, with local recurrence occurring in 2 of those cases (time to recurrence, 2 and 10 months).
Chemotherapy was administered in 4 cases, but did not result in significant improvement. All 9 cases died of lung
metastases, with a median survival time of 10 (range, 3.4-18.8) months. The presence of initial metastasis at
diagnosis was a significant unfavorable prognostic factor.
Conclusion: The prognosis of dedifferentiated chondrosarcoma is dismal. With the lack of convincing evidence of
the benefit of chemotherapy, complete surgical excision is the initial recommended treatment.Background
Dedifferentiated chondrosarcomas consist of two distin-
guishable components: low-grade chondrosarcoma com-
ponents and high-grade dedifferentiated components.
This group of cancers was first described in 1971 [1].
The dedifferentiated components have varying features,
including features of undifferentiated sarcomas, osteo-
sarcomas, angiosarcomas, fibrosarcomas, rhabdomyosar-
comas, leiomyosarcomas, and giant cell tumors [2].
Dedifferentiated chondrosarcomas are highly malignant
with a very poor prognosis [3,4]. Surgery is the primary
treatment modality, and chemotherapy has been adapted
for use in selected cases with dedifferentiated chondro-
sarcoma [2,4,5]. In the current report, a series of* Correspondence: akio@med.kyushu-u.ac.jp
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reproduction in any medium, provided the ordedifferentiated chondrosarcoma cases treated in our in-
stitute is examined, with a focus on identification of
prognostic factors.
Materials and methods
Between 1996 and 2010, 9 cases of dedifferentiated
chondrosarcoma were treated in our institute. All cases
had been referred to our institute by nearby hospitals.
Clinical information of these cases is presented in
Table 1. The cases included 4 males and 5 females. The
mean age at the first procedure was 58.6 years (range, 37
to 86 years). The tumor location was the long bone in 7
cases (femur, n=5; humerus, n=1; tibia, n=1). In the
other 2 cases, tumors were located in non-long bone
(pelvic bone in both cases). Biopsy was performed in all
cases for the purpose of diagnosis. Surgery was per-
formed in 8 cases, while 1 case received palliative care
only.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical information of cases with dedifferentiated chondrosarcoma











#1 53/F Femur 9 m + - WR - Initial DOD (3.4 m)
#2 37/F Tibia 2 m + + WR + (10 m) 9 m DOD (14.1 m)
#3 71/M Pelvis 24 m + - IR - Initial DOD (5.0 m)
#4 59/M Humerus 40 m + + WR + (2 m) 4 m DOD (10 m)
#5 54/F Pelvis 3 m + + MR - Initial DOD (9.1 m)
#6 71/F Femur 3 m + - WR - 15 m* DOD (18.8 m)
#7 44/M Femur 2 m + + WR - 10 m DOD (14.0 m)
#8 73/M Femur 1 m + - WR - Initial DOD (6.7 m)
#9 86/F Femur 1 m + - - NA Initial DOD (5.0 m)
F, female; M, male; PD, progressive disease; WR, wide resection; IR, intralesional resection; MR, marginal resection; M, months; NA, not assessed; *, as well as bone
metastasis; DOD, died of disease.
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tute were assessed. They were evaluated with respect to
matrix mineralization, bone destruction, and the pres-
ence of fracture. The presence of extraskeletal extension
was assessed by magnetic resonance imaging (MRI). Sur-
gical treatment was performed by either resection alone
or resection followed by implantation of an endoprosth-
esis. Chemotherapy was administered to select cases.Statistical analysis
The survival estimates were determined by Kaplan-
Meier analysis, while the survival differences according
to clinical parameters (lung metastasis, local recurrence,
and location) were evaluated by the log-rank test. A P
value of less than 0.05 was considered to indicate statis-
tical significance.Results
Time from the appearance of symptoms to treatment
ranged from 1 to 40 months, with an average of 9.4
months and a median of 3 months. All 9 cases presented
with pain (100%). A palpable mass was detected in 3 of
the 9 cases (33%), including 1 humerus case and 2 femur
cases. Numbness was observed in 1 of the 9 cases (11%),
a femur case (Table 2).
On plain radiographs, matrix mineralization was
observed in all 9 cases (100%). Bone destruction was de-
tectable in 5 of the 9 cases (56%). Pathological fracture
was observed in 1 femur case (11%). On MRI, extraske-










58.6 4/5 7/2 9/9 3/9 1/9
(100) (33%) (11%)
M, male; F, female.the cases with bone destruction on plain radiographs
had extraskeletal extension on MRI (Table 2).
Eight of the nine cases were managed with surgery
(89%), while the other one case received non-surgical
palliative care only. This latter patient was an 86-year-
old woman with dedifferentiated chondrosarcoma in the
femur who refused to undergo amputation. Among the
8 cases who underwent surgery, 6 cases were given a
wide surgical margin (75%), 1 case was given a marginal
margin (13%), and 1 case underwent intralesional resec-
tion (13%). In the long bone cases, wide resection was
performed in all 6 cases. In contrast, in the pelvic bone
cases, 1 case was given a marginal margin, while the
other case underwent intralesional resection (Table 1).
Chemotherapy was given to 4 patients following surgi-
cal tumor resection. The chemotherapy regimen consisted
of adriamycin, ifosfamide, cisplatin, and methotrexate.
Lung metastasis was observed in all cases (initially in 5
cases; during the treatment course in 4 cases). In one
case, bone metastasis was seen in addition to the lung
metastasis. Time to lung metastasis ranged from 4 to 15
months, with an average of 9.5 months. Local recurrence
following resection occurred in 2 of the 8 surgery cases,
at 2 and 10 months. Both of these local recurrence cases
had undergone amputation (Table 1).
The median survival time was 10 months, with a mean
survival time of 10.1 months, ranging from 3.4 to 18.8
months (Table 1, Figure 1a). All 9 cases died of lung me-
tastases. The presence of metastasis at diagnosis was a
significant unfavorable prognostic factor (Figure 1b).







9/9 5/9 1/9 6/9
(100%) (56%) (11%) (67%)
Figure 1 (a) Kaplan-Meier survival curve for all 9 cases with dedifferentiated chondrosarcoma, showing a mean survival time of 10
months. (b) Overall survival curves comparing cases with lung metastasis at the initial visit and those without; the difference is significant.
(c) Overall survival curves comparing cases with local recurrence and those without. (d) Overall survival curves comparing cases in the trunk and
those in the extremities.
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and 14 months in cases without metastases at diagnosis
(mean survival time, 14.2 months). No significant differ-
ence in survival based on local recurrence was observed;
the mean survival time was 12.1 months in cases with
local recurrence and 9.5 months in cases without local
recurrence (Figure 1c). Patients with trunk tumors
tended to have shorter survival (mean, 7.1 months; me-
dian, 5 months) than patients with extremity tumors
(mean, 10.3 months; median, 10 months) (Figure 1d).
Neither gender nor age were significant factors. No sig-
nificant difference in survival was noted between cases
that received chemotherapy and those who did not.
However, the median survival time was 11.8 months for
the 4 cases who received chemotherapy (mean survival
time, 12 months) while it was 9.1 months for the cases
who did not receive chemotherapy (mean survival time,
7.8 months).
Discussion
Dedifferentiated chondrosarcoma is known to have a
poor prognosis. Median survival has been as short as 6
months, and 5-year survival rates may be as low as 10%
to 13%. Patients rarely survive for more than 2 years
[3,4]. Consistent with the reported unfavorable progno-
sis, all current cases died of lung metastases, with a me-
dian survival time of only 10 months (range, 3.4 to 18.8
months). In two very recent reports, the median survival
time was 7.5 months [6] and 1.4 year [5], and the overall5-year survival rate was 7.1% [6] and 24% [5], respect-
ively. The prognosis of dedifferentiated chondrosarcoma
has shown a slow improvement trend over time, pre-
sumably due to earlier diagnosis and improved staging
and treatment [5].
Metastasis, especially to the lung, is the most import-
ant treatment problem in patients with dedifferentiated
chondrosarcoma [5-7]. In the current study, the presence
of metastases at diagnosis was a significant unfavorable
prognostic factor. Chemotherapy is an option for control
of metastatic lesions. However, the value of chemother-
apy for cases with dedifferentiated chondrosarcoma has
not been supported [2,4]. In addition to the lack of con-
vincing evidence of the benefit of chemotherapy, the tox-
icity of chemotherapy experienced by older patients with
dedifferentiated chondrosarcoma generally rules it out as
a standard treatment [5]. However, in a previous report,
2 out of 13 patients with dedifferentiated chondrosar-
coma experienced a good response to chemotherapy,
demonstrating more than 90% necrosis [5]. These results
suggest a possible benefit of chemotherapy for some
patients with dedifferentiated chondrosarcoma.
The prognosis of patients with dedifferentiated chon-
drosarcoma can be improved by an accurate preoperative
diagnosis [8]. Characteristically on plain radiographs, a
combined pattern composed of the aggressive parts of
dedifferentiated chondrosarcoma components and the less
aggressive parts of well-differentiated chondrosarcoma
components suggests dedifferentiated chondrosarcoma
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chondrosarcoma, osteolytic lesions associated with cor-
tical destruction have been reported in the majority of
cases on plain radiographs [9]. In the current study,
bone destruction was present in about half of the cases
on plain radiographs, and all of these cases demon-
strated extraskeletal extension on MRI. The presence of
matrix mineralization, indicative of a cartilaginous
tumor, accompanied by bone destruction of an aggres-
sive nature may suggest a diagnosis of dedifferentiated
chondrosarcoma based on plain radiographs.
It is important to distinguish between conventional
chondrosarcoma and dedifferentiated chondrosarcoma,
considering the greatly different prognosis [2]. A patho-
logical diagnosis would be inaccurate if the biopsy sam-
ple contained just one component of dedifferentiated
chondrosarcoma. Therefore, a carefully planned biopsy
based upon MRI, assessing each component of dedifferen-
tiated chondrosarcoma, is essential. Even if only one com-
ponent—either a conventional chondrosarcoma component
or a dedifferentiated component—is detected in the patho-
logical sample, possible dedifferentiated chondrosarcoma
should be considered in cases in whom plain radiographs
show matrix mineralization with a destructive aggressive
feature.
Local control by surgery does not appear to be related
to prognosis [5-7]. This observation seems to emphasize
the importance of not only local control, but also control
regarding metastasis, which is directly associated with
the prognosis. However, surgical treatment for local con-
trol is still an important procedure for dedifferentiated
chondrosarcoma. Local recurrence has been reported in
up to 50% of cases after excision, with much better local
control when there is adequate, or wide, resection [3-5].
In the current study, local recurrence was seen in 2 out
of 6 cases treated with wide resection, including 1 case
in the tibia and 1 case in the humerus. Since the tibia
and humerus are close to essential vessels, the creation
of an adequate surgical margin intended to prevent local
control may be difficult.
Regarding the pathogenesis of dedifferentiated chon-
drosarcoma, no structural or numerical chromosomal
aberrations that are highly specific for dedifferentiated
chondrosarcomas have been identified. However, some
evidence has suggested clustering of breakpoints in spe-
cific regions of 6q13-22 and 9p21-24 in dedifferentiated
chondrosarcoma [10]. High-grade dedifferentiated com-
ponents have been shown to have a higher malignant
potential than low-grade chondrosarcoma components,
with increased proliferation as demonstrated by expres-
sion of Ki-67 and proliferating cell nuclear antigen [11].
The plasminogen activator system is a key regulator of
invasion and tumor angiogenesis. Plasminogen activator
inhibitor 1 (PAI-1) acts as an inhibitor of tissue-typeplasminogen activator (tPA) and urokinase-type plas-
minogen activator (uPA) [12]. In dedifferentiated chon-
drosarcoma, high-grade dedifferentiated components
display diffuse coexpression of t-PA, u-PA, and PAI-1
[13]. Matrix metalloproteinases (MMPs) are a family of
zinc-dependent endopeptidases that are principally
involved in the breakdown of the extracellular matrix, as
well as in tumor angiogenesis [14]. Upregulation of
MMP2 and MT1-MMP has been reported in high-grade
malignant cartilaginous tumors, as well as in the high-
grade dedifferentiated component of dedifferentiated
chondrosarcoma [15].
Conclusion
The current study describes a series of dedifferentiated
chondrosarcoma cases treated in our institute. The pres-
ence of initial metastasis at diagnosis was a significant
unfavorable prognostic factor. The prognosis of dediffer-
entiated chondrosarcoma remains dismal. With the lack
of convincing evidence of the benefit of chemotherapy
for dedifferentiated chondrosarcoma, including what
constitutes standard treatment, its use in this patient
population remains controversial. Complete surgical ex-
cision should be the initial treatment for patients with a
dedifferentiated chondrosarcoma, with chemotherapy
reserved for palliative purposes.
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